RAS Dialogue Blog

Nature’s own delivery system meets precision oncology: the decade-long journey of engineered exosomes to a first-in-human KRAS trial.

New structures reveal how LZTR1 recognizes inactive RAS proteins for degradation, opening a new path to therapeutically eliminate oncogenic KRAS.

From KRAS G12D to KRAS G12R, new research uncovers how each mutation drives pancreatic cancer differently—and why it matters for patient outcomes.

KRAS mutants don’t just anchor to membranes—they choose their lipid partners. Discover how this specificity could unlock new cancer therapies.

Understanding and overcoming resistance to KRAS G12C inhibitors remains a key focus in the fight against RAS-driven cancers. Experts describe non-genetic methods of resistance to G12C inhibitors that bind to the inactive, GDP-bound form of the protein, and propose the best therapeutic strategy.

Post-doc Robin A Jansen and her advisor Rene Bernards lay out a compelling argument for MAP2K4 inhibition as an effective combination therapy with RAS-targeted drugs.

Measuring active RAS levels in live cells has long been a challenge—until now. Discover how AI-designed biosensors reveal where and how Ras signals inside cells, reshaping cancer research.

Learn about how top-down proteomics uncovered novel KRAS proteoforms, and how this gives us a better understanding of colorectal cancer.

Drs. Fuyuhiko Tamanoi, Hideyuki Saya, Toshio Imai, and Kiyoko Kato present a report of the online meeting that they organized, titled “Development of mutant KRAS molecular target drugs and future prospects.”

Senescent macrophages fuel KRAS-driven lung cancer and suppress immunity. Discover how targeting them could halt tumors before they start—and boost survival.